Non-small cell lung adenocarcinoma is less malignant than small cell lung cancer, but it is also a malignant tumor and more serious. If there is no metastasis and the stage is early, long survival time can be achieved after early and standardized treatment. Non-small cell lung cancer, including squamous, adenocarcinoma, and large cell lung cancer, grows more slowly and metastasizes later compared with small cell lung cancer, and there are still chances of surgery for patients with stage 1, stage 2, and stage 3A. After surgery, the 5-year survival rate of stage 1 patients may reach 70%, that of stage 2 patients may reach 50%, and that of stage 3 patients may reach 30% if they are able to have surgery combined with chemotherapy, but the prognosis may also be affected by the individual’s physical condition and the presence of underlying diseases. It is suggested that non-small cell cancer patients should consult the doctor in time and standardize the treatment under the doctor’s guidance, so as to improve the survival rate as well as the quality of life.